Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 6Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 104Colorectal Neoplasms 63Stomach Neoplasms 49Rectal Neoplasms 42Colonic Neoplasms 24Neoplasm Metastasis 21Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Pancreatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 12Neoplasms 12Gallbladder Neoplasms 7Cholangiocarcinoma 7Adenocarcinoma 6Esophageal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Esophageal Squamous Cell Carcinoma 4Neuroendocrine Tumors 3Gastrointestinal Neoplasms 3Digestive System Neoplasms 3Bile Duct Neoplasms 3Recurrence 2Pathologic Complete Response 2Liver Neoplasms 2Intestinal Neoplasms 2Hand-Foot Syndrome 2HER2-positive Advanced Breast Cancer 2HER2 Positive Metastatic Breast Cancer 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

aflibercept 3Irinotecan 2Bevacizumab 2XELOX 1Vemurafenib 1Panitumumab 1Leucovorin 1IFL protocol 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colorectal Cancer Metastatic × Capecitabine × Clear all
NCT01249638 2011-03-14

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Ludwig-Maximilians - University of Munich

Phase 3 Unknown
516 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡